T. Rowe Price Associates
ANIP icon

T. Rowe Price Associates’s ANI Pharmaceuticals ANIP Stock Holding History

T. Rowe Price Associates’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.42M Buy
17,098
+3,615
+27% +$290K ﹤0.01% 2164
2026
Q1 		$1.04M Buy
13,483
+2,930
+28% +$229K ﹤0.01% 2135
2025
Q4 		$834K Buy
10,553
+850
+9% +$73.6K ﹤0.01% 2156
2025
Q3 		$889K Buy
9,703
+481
+5% +$39.2K ﹤0.01% 2122
2025
Q2 		$602K Buy
9,222
+1,133
+14% +$73.8K ﹤0.01% 2217
2025
Q1 		$542K Buy
8,089
+801
+11% +$47.8K ﹤0.01% 2220
2024
Q4 		$403K Buy
7,288
+1,220
+20% +$70K ﹤0.01% 2373
2024
Q3 		$363K Buy
6,068
+186
+3% +$11.3K ﹤0.01% 2389
2024
Q2 		$375K Buy
5,882
+1,713
+41% +$111K ﹤0.01% 2308
2024
Q1 		$289K Buy
+4,169
New +$252K ﹤0.01% 2449

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates's ANIP Position: Q2 2026 in Review

T. Rowe Price Associates increased its ANI Pharmaceuticals (ANIP) stake by 27% in Q2 2026, buying an estimated $290K and bringing the position to 17,098 shares worth $1.42M. The position accounts for ﹤0.01% of the portfolio, ranked #2164.

T. Rowe Price Associates first reported a position in ANIP in Q1 2024 and has held it in 10 quarters since. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • T. Rowe Price Associates held 17,098 shares of ANI Pharmaceuticals worth $1.42M as of Q2 2026.
  • T. Rowe Price Associates bought 3,615 ANI Pharmaceuticals shares in Q2 2026, an estimated $290K.
  • ANI Pharmaceuticals made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2164 holding.
  • T. Rowe Price Associates first reported a position in ANI Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • 307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.